Kairon Labs and Solidus Labs Partner to Redefine Ethical Market Making Under MiCA
12.12.2024 15:00:00 CET | Business Wire | Press release
Kairon Labs, a leading crypto market maker and liquidity provider, has partnered with Solidus Labs, a pioneer in crypto-native compliance and risk management solutions, to strengthen its compliance program and ensure readiness for the European Union's upcoming Markets in Crypto-Assets Regulation (MiCA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212677489/en/
Solidus Labs enters partnership with Kairon Labs (Graphic: Business Wire)
With a proven track record of supporting over 500 digital asset issuers across more than 100 exchanges, Kairon Labs is committed to ethical market-making practices that promote transparency and fairness in the crypto space. By integrating Solidus Labs' trade surveillance technology, Kairon Labs aims to proactively monitor and mitigate market manipulation risks across its operations, reinforcing its dedication to market integrity.
"As regulatory environments become increasingly stringent, it's imperative to uphold the highest standards of compliance," said Jens Willemen, Co-Founder and CEO of Kairon Labs. "Solidus Labs has proven to be the ideal partner for us, thanks to their unmatched expertise in trade surveillance and profound comprehension of the cryptocurrency landscape, especially in the context of the Markets in Crypto-Assets (MiCA) regulation. Their advanced detection algorithms, combined with a holistic compliance platform, align seamlessly with our vision of ensuring a secure trading environment for our clients while maintaining market integrity at every level."
Solidus Labs, a trusted partner for institutions dedicated to crypto integrity, provides Kairon Labs with a robust market integrity toolkit. From real-time anomaly detection to precision-driven behavioral insights, this collaboration will enable thorough monitoring and effective detection of suspicious activities across Kairon’s operations.
"By championing transparency, innovation, and trust, Kairon Labs is shaping the future—one where markets aren’t just made—they’re made better," said Asaf Meir, CEO and Founder of Solidus Labs. "With Solidus, they’re not just prepared for MiCA—they’re setting the gold standard for safe, forward-looking market making. Together, we’re building the foundation for the financial markets of tomorrow."
With MiCA’s sweeping anti-market abuse mandates set to take effect on December 30, 2024, the timing of this collaboration couldn’t be more pivotal. Kairon Labs is demonstrating that in market making, liquidity flows to safety and that market integrity is not just a responsibility—it’s a competitive advantage.
About Kairon Labs:
Kairon Labs is a premier crypto market maker and liquidity provider, offering bespoke algorithmic trading solutions to digital asset issuers. With a focus on ethical market-making practices, Kairon Labs has supported over 500 clients, ensuring successful token launches and sustained market stability. For more information, visit: Kairon Labs
About Solidus Labs
Solidus Labs is the category-definer for crypto-native security and compliance solutions: trade surveillance, transaction monitoring, and staking guard. Solidus Labs leads initiatives like the Crypto Market Integrity Coalition and the DACOM Summit, with a commitment to safe crypto trading across centralized and decentralized markets. For more information, visit: https://soliduslabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212677489/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom